



Clinical trial results: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV

Summary

EudraCT number	2014-002384-15
Trial protocol	AT
Global end of trial date	30 April 2018

Results information

Result version number	v1 (current)
This version publication date	16 November 2019
First version publication date	16 November 2019

Trial information

Trial identification

Sponsor protocol code	3.0
-----------------------	-----

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Medical University of Vienna
Sponsor organisation address	Spitalgasse 23, Vienna, Austria, 1090
Public contact	MUW, Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, +43 14040079310, stefan.sacu@meduniwien.ac.at
Scientific contact	MUW, Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, +43 14040079310, stefan.sacu@meduniwien.ac.at

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	02 September 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	30 April 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To investigate the effect of intravitreal Aflibercept treatment on the visual outcome in patient with exsudative maculopathies such as Rap-lesions, PED, hemorrhagic CNV and PCV.

Protection of trial subjects:

Intravitreal aflibercept therapy is considered to be safe. As with every intravitreal form of therapy, the potential for post-injection IOP elevation, endophthalmitis, cataract, hemorrhage, rhegmatogenous retinal detachment or proliferative vitreoretinopathy must be considered. However, all of these side effects have an incidence of less than 1% of all treatments.

After intravitreal injections, visual acuity of patient will be checked (e.g. hand motion, counting fingers) to avoid unacceptable IOP elevations and ensure ocular perfusion-in cases of blocked ocular perfusion (i.e. the patient is unable to recognize hand motion/finger counting), a paracentesis will be performed by the surgeon

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 November 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 50
Worldwide total number of subjects	50
EEA total number of subjects	50

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	3
From 65 to 84 years	35
85 years and over	12

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Fifty patients will be enrolled in the study. The population will consist patients over 50 years of age with treatment naïve, RAP-lesions, PED, hemorrhagic CNV and polypoidal choroidal vasculopathy.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All Patients
-----------	--------------

Arm description:

Evaluation of intravitreal aflibercept (Eylea®, Bayer) on oxygen saturatin and clinical outcomes in eyes with RAP-lesions, PED, hemorrhagic CNV or PCV.

Arm type	Intervention
Investigational medicinal product name	Intravitreal aflibercept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Intravitreal use

Dosage and administration details:

2mg/0.05ml

Number of subjects in period 1	All Patients
Started	50
Completed	43
Not completed	7
Lost to follow-up	7

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	50	50	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	77		
full range (min-max)	60 to 88	-	
Gender categorical			
Units: Subjects			
Female	36	36	
Male	14	14	

End points

End points reporting groups

Reporting group title	All Patients
Reporting group description: Evaluation of intravitreal aflibercept (Eylea®, Bayer) on oxygen saturation and clinical outcomes in eyes with RAP-lesions, PED, hemorrhagic CNV or PCV.	

Primary: Oxygen saturation of retinal vessels

End point title	Oxygen saturation of retinal vessels ^[1]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

12 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Anova and the paired t-test was performed to investigate the longitudinal changes in visual acuity, the central retinal thickness, retinal vessel diameters, retrobulbar flow velocities and retinal blood flow. A p-value ≤ 0.05 is considered as statistical significant. Descriptive analysis will be performed for patient's demographic data, furthermore, chi²-Test was used for nominal parameters.

End point values	All Patients			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Percentage	95			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events, serious adverse events are collected by spontaneous reporting during the study period. Nonserious adverse events and SUSARs are documented on an "Adverse event" page in the case record form.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	17

Reporting groups

Reporting group title	Aflibercept
-----------------------	-------------

Reporting group description:

intravitreal aflibercept treatment will be performed identically under sterile conditions in the surgery room as follows: 0,5ml of 2 mg of commercially available aflibercept (Eylea®; Bayer) will be applied intravitreal through the pars plana using a 30-gauge needle

Serious adverse events	Aflibercept		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 50 (10.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Palate cancer			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Apoplexy			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Pacemaker			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			

Hemorrhage	Additional description: Visual reduction due to new hemorraghe		
	subjects affected / exposed	1 / 50 (2.00%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	
Reproductive system and breast disorders			
Mastectomy			
	subjects affected / exposed	1 / 50 (2.00%)	
	occurrences causally related to treatment / all	0 / 1	
	deaths causally related to treatment / all	0 / 0	

Frequency threshold for reporting non-serious adverse events: 4 %

Non-serious adverse events	Aflibercept		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 50 (10.00%)		
Nervous system disorders			
Polyneuropathy			
Additional description: Polyneuropathy legs			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Eye disorders			
Visual acuity reduced			
Additional description: Visual loss due to increase of SRF and PED			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Cataract operation			
Additional description: Cataract operation both eyes			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Infections and infestations			
Antibiotic therapy			
Additional description: Antibiotic Dalcin			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported